Gene Therapy of Cochlear Deafness

Present Concepts and Future Aspects

Editor(s): Ryan A.F. (La Jolla, Calif.) 
Table of Contents
Vol. 66, No. , 2009
Section title: Paper
Ryan AF (ed): Gene Therapy of Cochlear Deafness. Adv Otorhinolaryngol. Basel, Karger, 2009, vol 66, pp 37–51

Gene Therapy in the Inner Ear Using Adenovirus Vectors

Husseman J.a · Raphael Y.b
aDivision of Otolaryngology-Head and Neck Surgery, University of California, San Diego, Calif., and bKresge Hearing Research Institute, Department of Otolaryngology, University of Michigan, Ann Arbor, Mich., USA


Therapies for the protection and regeneration of auditory hair cells are of great interest given the significant monetary and lifestyle impact of hearing loss. The past decade has seen tremendous advances in the use of adenoviral vectors to achieve these aims. Preliminary data demonstrated the functional capacity of this technique as adenoviral-induced expression of neurotrophic and growth factors protected hair cells and spiral ganglion neurons from ototoxic insults. Subsequent efforts confirmed the feasibility of adenoviral transfection of cells in the auditory neuroepithelium via cochleostomy into the scala media. Most recently, efforts have focused on regeneration of depleted hair cells. Mammalian hearing loss is generally considered a permanent insult as the auditory epithelium lacks a basal layer capable of producing new hair cells. Recently, the transcription factor Atoh1 has been found to play a critical role in hair cell differentiation. Adenoviral-mediated overexpression of Atoh1 in culture and in vivo have shown the ability to regenerate auditory and vestibular hair cells by causing transdifferentiation of neighboring epithelial-supporting cells. Functional recovery of both the auditory and vestibular systems has been documented following adenoviral induced Atoh1 overexpression.

 goto top of outline Author Contacts

Yehoash Raphael, Department of Otolaryngology, Kresge Hearing Research Institute, Rm. 9301 MSRB-3, Ann Arbor, MI 48109–5648 (USA), Tel. +1 734 936 9386, Fax +1 734 615 8111, E-Mail

 goto top of outline Article Information

Published online: June 02, 2009
Number of Print Pages : 15

 goto top of outline Publication Details

Book Serie: Advances in Oto-Rhino-Laryngology, Vol. 66, Year 2009

Editor(s): Arnold, W. (München)
ISSN: 0065-3071 (Print), eISSN: 1662-2847 (Online)

For additional information:

Book Title: Gene Therapy of Cochlear Deafness (Present Concepts and Future Aspects)

Editor(s): Ryan AF (ed)

For additional information:

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.